BCAB (BioAtla) Valuation Rank

View and export this data going back to 2020. Start your Free Trial

What is BioAtla Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioAtla Valuation Rank Related Terms

Thank you for viewing the detailed overview of BioAtla's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAtla Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

11085 Torreyana Road, San Diego, CA, USA, 92121

Website

https://www.bioatla.com

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Executives

Sylvia Mcbrinn	director
Short Jay M Phd	director, 10 percent owner, officer: Chief Executive Officer	C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez	officer: See Remarks	121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith	director, officer: President	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers	officer: Chief Medical Officer	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron	officer: Chief Financial Officer	901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy	director, 10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc	10 percent owner	104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc	10 percent owner	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran	director	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short	10 percent owner, officer: See Remarks	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142